Lovaltech

Lovaltech is developing a new-generation muco-excipient platform designed to optimize the intranasal administration of complex biomolecules, whether recombinant proteins, mRNA, or other innovative formats.

This proprietary technology is based on a modular nanoparticle architecture capable of increasing adhesion and persistence in the mucosa, protecting sensitive biological entities, promoting their local internalization, and inducing robust mucosal and systemic immunity, a goal that has become central to future respiratory vaccines.

Completely agnostic in terms of vaccine format, the platform paves the way for the development of intranasal protein vaccines, already validated in Phase I human trials with an excellent safety profile, as well as the exploration of mRNA vaccines specifically formulated for the nasal route, an area that has yet to be fully explored but offers major prospects. In the longer term, its delivery and immunomodulation properties also open up applications beyond infectious diseases, particularly in the fields of therapeutic vaccination and oncology.

IDCluster’s pre-acceleration program will support Lovaltech in the industrial, regulatory, and IP structuring of this NextGen platform, with the ambition of making it a benchmark European technological foundation for future high-value-added nasal administration candidates.